Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Breast Neoplasms 2Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1

Interventions

Cytarabine 7Idarubicin 3Etoposide 3Daunorubicin 3Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Methotrexate 2Cyclophosphamide 2Clofarabine 2valspodar 1tipifarnib 1pegylated granulocyte colony-stimulating factor 1fludarabine phosphate 1enasidenib 1aldesleukin 1Whole-Body Irradiation 1Vorinostat 1Topotecan 1Pravastatin 1Mycophenolic Acid 1Mitoxantrone 1Lenalidomide 1Gemtuzumab 1Cyclosporine 1Calicheamicins 1Busulfan 1Bortezomib 1Bone Marrow Transplantation 1Biopsy 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Leukemia, Monocytic, Acute × Antineoplastic Agents × Clear all
NCT00831766 2020-12-22

Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Completed
51 enrolled 11 charts
MyeloidOther hematologic neoplasm

Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡